Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0001172661-25-003543
Filing Date
2025-08-14
Accepted
2025-08-14 17:26:24
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G  
1 primary_doc.xml SCHEDULE 13G 9407
  Complete submission text file 0001172661-25-003543.txt   11342
Mailing Address 22722 29TH DR. SE SUITE 100 SEATTLE WA 98021
Business Address 22722 29TH DR. SE SUITE 100 SEATTLE WA 98021 425-686-1500
ACHIEVE LIFE SCIENCES, INC. (Subject) CIK: 0000949858 (see all company filings)

EIN.: 954343413 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G | Act: 34 | File No.: 005-45969 | Film No.: 251221187
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)

Mailing Address 77 WEST WACKER DRIVE 7TH FLOOR CHICAGO IL 60601
Business Address 77 WEST WACKER DRIVE 7TH FLOOR CHICAGO IL 60601 312-899-7902
Alyeska Investment Group, L.P. (Filed by) CIK: 0001453072 (see all company filings)

EIN.: 261919051 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G